Pemetrexed

Pemetrexed 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-small Cell Lung Cancer、Carcinoma, Non-Small-Cell Lung、Locally Advanced Non-Small Cell Lung Cancer (NSCLC)、Metastatic Non-Small Cell Lung Cancer (NSCLC)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Pemetrexed 研究

• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  II 期招募中美国NCT06745882

• JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

  III 期招募中中国NCT06416410

• Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

  II 期招募中中国NCT07492342

• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  II 期招募中美国加拿大中国South KoreaNCT07586202

• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  II 期招募中美国Argentina澳大利亚BrazilNCT07680764

• A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

  II 期招募中美国ChileGreeceHungaryNCT06731907

• Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

  II 期招募中美国NCT05681195

• Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

  II 期招募中中国NCT03872661

• Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

  II 期招募中美国NCT06865339

• A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

  II 期招募中中国NCT06769295

• BBO-11818 in Adult Subjects With KRAS Mutant Cancer

  I 期招募中美国澳大利亚NCT06917079

• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

  II 期招募中美国澳大利亚比利时BrazilNCT07415031

• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  不适用招募中奥地利比利时Czechia德国NCT07230691

• A Study of ASP1002 in Adults for Treatment of Solid Tumors

  I 期招募中美国NCT05719558

• A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

  I 期 / II 期招募中美国法国德国意大利NCT05443126

• Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

  I 期招募中美国澳大利亚加拿大中国NCT06384352

• CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

  I 期 / II 期招募中美国澳大利亚法国爱尔兰NCT07335497

• Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

  II 期招募中美国NCT07405190

• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

  II 期招募中中国NCT07304739

• Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

  I 期 / II 期招募中美国NCT04486833

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  III 期招募中美国Argentina澳大利亚比利时NCT06627647

• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

  不适用招募中中国NCT06643000

• Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  III 期招募中美国Argentina澳大利亚BrazilNCT07680790

• Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

  II 期招募中加拿大NCT04335292

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。